Skip header and navigation

4 records – page 1 of 1.

Azathioprine and Mercaptopurine Therapy

https://libcat.nshealth.ca/en/permalink/chpams35565
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1079
Available Online
View Pamphlet
This pamphlet will help you decide if azathioprine (Imuran®) or mercaptopurine therapy is right for you. The pamphlet explains what azathioprine (AZA) and mercaptopurine (6-MP) are, how well they work, as well as serious and less serious side-effects. The pamphlet also includes a list of what you can do to lower the chances of side-effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (6 p.): digital, PDF file
Subjects (MeSH)
Immunosuppressive Agents
Azathioprine
Mercaptopurine
Subjects (LCSH)
Immunosuppressive agents
Specialty
Medications
Abstract
This pamphlet will help you decide if azathioprine (Imuran®) or mercaptopurine therapy is right for you. The pamphlet explains what azathioprine (AZA) and mercaptopurine (6-MP) are, how well they work, as well as serious and less serious side-effects. The pamphlet also includes a list of what you can do to lower the chances of side-effects.
Notes
Previous title: Azathioprine (Imuran) therapy
Responsibility
Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
Pamphlet Number
1079
Less detail

Corticosteroid therapy in inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35480
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1546
Available Online
View Pamphlet
Corticosteroids (kor-ti-koh-STER-oids) are strong inhibitors of inflammation (swelling). To ‘inhibit’ means to slow down or cut down on something. This pamphlet explains what corticosteriods do, how they work, when they are used, and how they are given. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
Alternate Title
Corticosteroid therapy in IBD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Prednisone
Subjects (LCSH)
Inflammatory bowel diseases
Prednisone
Specialty
Gastrointestinal System
Medications
Abstract
Corticosteroids (kor-ti-koh-STER-oids) are strong inhibitors of inflammation (swelling). To ‘inhibit’ means to slow down or cut down on something. This pamphlet explains what corticosteriods do, how they work, when they are used, and how they are given. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
Notes
This pamphlet replaced pamphlet 1139, Prednisone Therapy.
Responsibility
Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
Pamphlet Number
1546
Less detail

Methotrexate (MTX) therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams34942
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1138
Available Online
View Pamphlet
Your health care provider feels that treatment with methotrexate (meth-oh-TREX-ate) might help your Crohn’s disease or ulcerative colitis. These are both types of inflammatory bowel disease (IBD). This pamphlet explains what methotrexate (MTX) is, how well it works, side effects of MTX, who should not take MTX, and precautions. Instructions for injecting MTX are given.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (13 p.) : digital, PDF file
Subjects (MeSH)
Methotrexate
Crohn's disease
Inflammatory Bowel Diseases
Immunosuppressive Agents
Subjects (LCSH)
Crohn's disease
Methotrexate
Immunosuppressive agents
Inflammatory bowel diseases
Specialty
Gastrointestinal System
Medications
Abstract
Your health care provider feels that treatment with methotrexate (meth-oh-TREX-ate) might help your Crohn’s disease or ulcerative colitis. These are both types of inflammatory bowel disease (IBD). This pamphlet explains what methotrexate (MTX) is, how well it works, side effects of MTX, who should not take MTX, and precautions. Instructions for injecting MTX are given.
Responsibility
Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
Pamphlet Number
1138
Less detail

Risankizumab (Skyrizi®) therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams38191
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
2345
Available Online
View Pamphlet
Risankizumab is a biologic medication. A biologic medication is a type of medication that treats inflammation. This pamphlet explains how risankizumab works, how it is given, and how long you can expect to take it. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Gastrointestinal System
Medications
Abstract
Risankizumab is a biologic medication. A biologic medication is a type of medication that treats inflammation. This pamphlet explains how risankizumab works, how it is given, and how long you can expect to take it. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
2345
Less detail